Frontiers

The 2026 journal impact metrics are here. More than numbers, they are proof of how quality research travels: read, cited, shared, and used around the world. Your research is the real superpower. We help it go further. Explore the latest metrics ⬇️ #QualityChampions

In a new guest post for The Scholarly Kitchen, Frontiers’ Director of Research Integrity, Elena Vicario, explores why clearer guidance is needed to ensure responsible AI use, supporting expert judgement while keeping accountability and trust at the centre. Read more ⬇️

@ArkAgResearch Useful findings for a fast-growing category. Congratulations to the team.

As non-alcoholic beer grows in popularity, what protects it from foodborne pathogens? New @AginArk research from @JenniferAcuff and @ScottLafontain shows how carbonation, hops and pH can work together to help inhibit foodborne pathogens. They published the results in @FrontMicrobiol. Read more: aaes.uada.edu/news/nab-food-… @ArkFoodSafety @uarkbumpers

@BLLPHD The focus on where a CAR T-cell targets mesothelin is especially interesting, given the challenge of shed antigen acting as a decoy. Thank you for sharing.

🚨NEW Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer Target antigen in cancer matter, so does where on that antigen is targeted. Mesothelin is attractive, but much of it is shed, leaving soluble antigen as a decoy and less target on the tumor. Here is a CAR to hit the membrane-proximal “stump” that remains after shedding. @FrontImmunol @PennMedicine frontiersin.org/journals/immun…

@HabibzadehMD @CureMelanoma @AIMatMelanoma @MelanomaReAlli @theNCI @MelanomaCanada @MelanomaAction @macmillancancer @diwakardavar @UPMC Congratulations on your publication in Frontiers in Immunology. Open access helps make important research like this accessible to everyone.

Excited to share our new case report in @FrontImmunol A patient with metastatic uveal melanoma on tebentafusp for >2 years had durable stable disease on imaging but autopsy showed extensive tumor necrosis + dense immune infiltration in liver metastases. Direct pathologic evidence of profound ImmTAC-driven anti-tumor immunity that imaging misses. frontiersin.org/journals/immun… @UPMCHillmanCC @Immunocore

“We are losing the battle of communication.” A blunt warning from THE Europe Universities Summit 2026. Science that isn’t communicated isn’t used. Open, connected research is the only way forward. #OpenScience #HigherEducation #ResearchImpact

@TechXplore_com The gap between high and low performers after just a short training session is notable, it suggests detection ability is teachable, not fixed. Thank you for sharing this.

Short training sharply improved people’s ability to spot AI-generated faces, with high performers reaching near perfection on some of the most convincing fakes. @ANUmedia @PNASNews @frontiersin techxplore.com/news/2026-06-s…

COPE Trustee Marie Soulière on why the relaunched COPE Paper Mill Working Group is gearing up with a new toolkit to help editors and institutions fight back👇 publicationethics.org/news-opinion/r… #ResearchIntegrity #PaperMills #COPE

@KingsNeuro @AbteenMostofi @The_SBNS Interesting question; conditions that look clinically distinct often share more at the level of mechanism than expected. Thank you for sharing this review.

Clinical manifestation of regional abnormal cortical plasticity: do dystonia and chronic pain have more in common than meets the eye? Published @FrontNeurol 👉 review of cortical reorganization, synaptic plasticity and impaired inhibitory control 🔗dx.doi.org/10.3389/fneur.…

@DrKhan_do @NIHRresearch @ARC_KSS @UniKentNews @UniKent What an achievement! Sharing your first-author publication in Frontiers in Medicine marks an important milestone.

Proud to share my first-author paper in @FrontMedicine on equity in applied health & care research training via the NIHR INSIGHT program, exploring structural competence, epistemic justice & inclusive pathways 🔗doi.org/10.3389/fmed.2… #HealthEquity #NIHR #PPI #AcademicPublishing

77% of researchers use AI in their work. 53% have seen it misused by peers. Most don't know where to find reliable guidance. Read the full piece 👇#LIBER2026 libereurope.eu/article/when-a…

@Paul_Sonnier Great work. Feasibility and adherence over a sustained period are often the hardest part of remote health monitoring, so results like this matter.

New in @FrontiersIn: @CumulusNeuro's NeuLogiq platform proved feasible for at-home EEG + cognitive testing in mild Alzheimer's across 52 weeks, with 77% adherence — supporting more sensitive dementia trials doi.org/10.3389/fdgth.… #DigitalHealth #Alzheimers

@theliverdoc This is a strong example of translating a complex retrospective study into something clinically useful and honest about its limits. Thank you for sharing your work in Frontiers in Pharmacology.

Dear Hepatology friends, and people caring for liver patients, we have a new paper out. Living with chronic liver disease can be incredibly overwhelming, and trying to navigate which supplements actually work can be just as confusing. Our study looking at glutathione, a very popular antioxidant supplement often prescribed for liver health, has just challenged the traditional "one-size-fits-all" approach to treatment. Instead of finding that glutathione works for everyone, we discovered that the supplement's effectiveness depends heavily on how sick the patient currently is. Here is the lay summary: ⭐Sicker patients actually improved more: Counter-intuitively, patients who were acutely ill with active, severe inflammation responded much better to glutathione than patients with stable liver disease. ⭐Longer treatment isn't always better: Taking glutathione for extended periods of time (beyond 15-day) did not provide any extra clinical benefit or improve survival. ⭐The "Ideal" patient profile: The highest success rates (where 70.5% of patients improved - with respect to disease severity) were seen in a very specific group: younger patients (under 60) with alcohol-associated liver disease, high active disease severity (MELD-3 score above 18), but who still had some baseline preserved liver function (albumin levels above 2.5). ⭐Inflammation is the key tracker: Patients whose inflammation markers (like C-reactive protein, or CRP) dropped during the treatment saw the most dramatic improvements in their overall liver disease scores and had much lower hospitalizations. For a long time, there has been a habit of indiscriminately prescribing glutathione to anyone with liver disease. This study strongly pushes back against that practice. Instead, it promotes a precision-medicine approach. Limitation: Because this study looked backward at past medical records (a retrospective study) without a placebo group, we cannot definitively prove that the supplement alone caused the improvements. To move forward, the medical community needs to conduct a rigorous, prospective randomized controlled trial. This future trial should specifically test glutathione versus a placebo on the "ideal" high-risk patients who have active systemic inflammation. Additionally, future researchers must measure specific, direct markers of oxidative stress in the blood to definitively prove that the supplement is working biologically the way we think it is. Full paper link: frontiersin.org/journals/pharm… via @FrontiersIn and @FrontPharmacol

What does the next chapter of #OpenScience look like? At #LIBER2026, Frontiers CEO Dr Kamila Markram will discuss how open collaboration, responsible AI, and research integrity can shape the future of research. Learn more ⬇️

Can technology solve environmental challenges? 🌍 The Top 10 Emerging Technologies of 2026 report, co-published by Frontiers and the World Economic Forum (@wef), highlights innovations tackling pollution and building more sustainable systems. Learn more ⬇️

What if cancer treatment could be tailored to every patient? Top 10 Emerging Technologies of 2026 highlights personalized mRNA cancer vaccines, exosome-based drug delivery, and quantum simulation for drug discovery—showing how trusted science is advancing precision medicine. ⬇️

Science belongs where decisions are made 🌍 Frontiers Science House hit the road with its first stop in Dalian, China, bringing leaders together to discuss the future of work, energy and climate technologies, and why trusted science must guide global decision-making.

China's innovation capacity is under the spotlight at the 2026 Summer Davos forum in Dalian, as participants believe that China's innovation-driven development will not only benefit itself, but also contribute to global growth and share opportunities with the world. #SummerDavos #ChinaInnovation #Innovation #AI #Technology #FutureGrowth

How will we meet growing energy demand while building a more resilient future? The Top 10 Emerging Technologies of 2026 report, co-published by Frontiers and @wef, highlights direct lithium extraction and everything-to-grid systems. Discover the science ⬇️

We're proud to share that Frontiers FAIR² Data Management is a finalist in the 2026 CODiE Awards for Best AI Data & Analytics Solution. A recognition of our mission to make research data discoverable, reusable, citable, and AI-ready. #CODiEAwards #FAIRData #ResearchData

@Infection_StAnd A real milestone that belongs to every author, reviewer, and editor who contributed to building Frontiers in Antibiotics. Thank you for being part of that community.

Delighted to see our first impact factor for Frontiers in Antibiotics. This is a credit to our authors, editors and journal staff for this achievement. Research to address antibiotic development and preventing resistance. @FrontiersIn @StAndMedicine @TBtrials_StAnd @BSACandJAC